Deep Phenotyping of Cutaneous Lupus Erythematosus - Trial NCT06411106
Access comprehensive clinical trial information for NCT06411106 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre for Human Drug Research, Netherlands and is currently Recruiting. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Centre for Human Drug Research, Netherlands
Timeline & Enrollment
N/A
Jun 01, 2024
Sep 01, 2025
Primary Outcome
Skin punch biopsies,3D Multispectral imaging,Laser Speckle Contrast Imaging (LSCI),Line-Field Confocal Optical Coherence Tomography (LC-OCT),Skin barrier function by Trans-Epidermal Water Loss (TEWL),Cutaneous microbiome,Lipidomics of the stratum corneum and OLINK,Blister immune cell subsets,Faecal microbiome (optional for patients),Circulating cytokines,Interferon (IFN) signature,User experience and subjective burden questionnaire
Summary
Cutaneous lupus erythematosus (CLE) is an autoimmune disease of which the pathogenesis and
 pathophysiology are not fully understood. Given the complex and heterogeneous character of
 the disease, identification, and development of specific biomarkers for diagnosis, disease
 subtyping, disease severity, and treatment response in CLE is challenging. Therefore, the
 main objective of the current study is to further characterize CLE by using a deep
 phenotyping approach. Moreover, the role of TLR7 activation in the pathophysiology of the
 various clinical subtypes of CLE will be specifically studied. With this approach the
 investigators aim to characterize objectively measured disease characteristics and detect
 novel biomarkers for CLE(-subtypes).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06411106
Non-Device Trial